Epigral Q3 Profit Halved on Margin Squeeze; Expansion Plans Underway

CHEMICALS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Epigral Q3 Profit Halved on Margin Squeeze; Expansion Plans Underway
Overview

Epigral Limited reported a steep 62% YoY drop in Q3 FY26 net profit to ₹39 Cr, driven by a 44% EBITDA fall and 1100 bps margin contraction to 17%. Revenue also declined 7% YoY. The company, however, is pushing forward with significant capacity expansions for CPVC and Epichlorohydrin, aiming for a stronger revenue mix from specialty chemicals by FY28.

📉 The Financial Deep Dive

The Numbers: Epigral Limited announced a challenging third quarter for FY26. Revenue for Q3 FY26 declined 7% year-on-year to ₹603 Cr (from ₹649 Cr in Q3 FY25), though it saw a marginal 2% sequential growth from ₹589 Cr in Q2 FY26. The company's operational profitability suffered significantly, with EBITDA dropping 44% YoY to ₹103 Cr (vs ₹183 Cr in Q3 FY25) and falling 22% QoQ to ₹103 Cr (vs ₹132 Cr in Q2 FY26). Profit After Tax (PAT) saw a drastic 62% YoY decrease to ₹39 Cr (from ₹104 Cr in Q3 FY25).

For the nine-month period (9MFY26), revenue stood at ₹1,807 Cr, down 7% YoY. EBITDA for 9MFY26 was ₹398 Cr, a 26% YoY decline, with an average margin of 22% compared to 28% in 9MFY25. The reported PAT for 9MFY26 of ₹251 Cr includes an ₹81 Cr deferred tax benefit; excluding this, the adjusted PAT would be ₹170 Cr, marking a 7% decrease from 9MFY25.

The Quality: The most concerning aspect is the severe contraction in EBITDA margins, which fell to 17% in Q3 FY26 from 28% in the prior year and 23% in the previous quarter. This was attributed to softer product realisations, higher raw material costs, and inventory dynamics. Key financial health indicators also showed deterioration: Return on Capital Employed (ROCE) and Return on Equity (ROE) slipped to 17% in Q3 FY26 from 23% in Q3 FY25. The Net Debt to EBITDA ratio increased to 1.0x from 0.8x, with Net Debt standing at ₹557 Cr.

The Grill: While the results paint a grim picture for the quarter, management expressed optimism for future outcomes. They highlighted a strategic focus on transitioning towards higher-value Derivatives & Specialty Chemicals, targeting a revenue share of approximately 70% from this segment by FY28E, up from 46% in FY25. Progress on significant capacity expansions for CPVC (75,000 TPA) and Epichlorohydrin (50,000 TPA), slated for commissioning in H1 FY27, was also emphasized as a key growth driver. Capex incurred in 9MFY26 was ₹337 Cr.

🚩 Risks & Outlook
The immediate risks involve the persistence of raw material cost pressures, potential inventory adjustments, and the ability to improve product realisations in a competitive market. The success of the planned capacity expansions and the strategic pivot to specialty chemicals will be critical for future performance. Investors will be watching the commissioning timelines and demand for the new capacities closely. Plant utilization at 78% in Q3 FY26 (stable QoQ but down YoY for 9MFY26) indicates room for improvement as new capacities come online.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.